Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.16M | 6.65M | 33.97M | 2.70M | 1.67M | Gross Profit |
578.00K | 4.05M | 24.43M | 2.70M | 1.67M | EBIT |
-92.10M | -39.23M | -36.69M | -130.26M | -109.94M | EBITDA |
-86.50M | -38.85M | -86.22M | -121.36M | -103.63M | Net Income Common Stockholders |
-112.96M | -42.81M | -37.56M | -128.69M | -103.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
82.65M | 43.89M | 32.25M | 217.43M | 262.39M | Total Assets |
306.12M | 61.77M | 35.15M | 263.74M | 310.57M | Total Debt |
50.84M | 44.73M | 4.97M | 15.44M | 0.00 | Net Debt |
-37.95M | 838.00K | -27.27M | -201.99M | -53.77M | Total Liabilities |
233.13M | 192.49M | 124.36M | 67.74M | 52.06M | Stockholders Equity |
72.99M | -130.71M | -89.21M | 196.00M | 258.51M |
Cash Flow | Free Cash Flow | |||
-96.46M | -13.44M | -33.14M | -98.06M | -113.19M | Operating Cash Flow |
-96.23M | -10.96M | -32.98M | -94.33M | -91.36M | Investing Cash Flow |
101.33M | -2.47M | -157.00K | 204.90M | -51.80M | Financing Cash Flow |
184.00K | 30.07M | 20.11M | 53.09M | 158.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.39 | -40.42% | 2.90% | 18.11% | 2.25% | |
42 Neutral | $20.01M | ― | -75.07% | ― | ― | 42.39% | |
41 Neutral | $22.81M | ― | -121.36% | ― | -100.00% | 91.45% | |
39 Underperform | $27.32M | ― | -182.35% | ― | ― | -220.54% | |
33 Underperform | $24.70M | ― | -91.76% | ― | ― | 57.93% | |
33 Underperform | $30.59M | ― | -3159.09% | ― | ― | 68.75% | |
32 Underperform | $27.13M | ― | -157.19% | ― | ― | -0.38% |
On April 25, 2025, Mark Iwicki announced his resignation from the board of directors of Q32 Bio Inc., effective December 31, 2025. He will maintain his roles as Chair of the Board and the Compensation Committee, and as a member of the Audit Committee until then. His resignation is to focus on his CEO role at Inhibikase Therapeutics, Inc., and is not due to any disagreements with Q32 Bio.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
To see Spark’s full report on QTTB stock, click here.
On February 10, 2025, Q32 Bio announced a strategic restructuring plan to focus on advancing its bempikibart clinical development program for alopecia areata. This involves discontinuing the Phase 2 renal basket trial of ADX-097 and evaluating strategic options for its tissue-targeted complement inhibitor platform. The restructuring includes a reduction in workforce and is expected to extend cash runway to the second half of 2026, while incurring approximately $1.1 million in severance charges. The company plans to initiate an open-label extension and SIGNAL-AA Part B dosing in 2025, with topline data expected in the first half of 2026. These changes aim to maximize the potential of bempikibart in transforming treatment for alopecia areata and potentially other autoimmune conditions.